The Canine Corner(Shorters Paradise) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Canine Corner(Shorters Paradise)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: DJRoss who wrote (29)	8/10/1998 8:16:00 AM
From: RockyBalboa	of 45

Zonagen Update Zonagen reports a loss of 6c a share for 2q 98. Revenues up mostly of the $5 M milestone fee from Schering, which came in accelerated, and a bit of royalties. Loss results from the devel. expenses up, attributed to the devel. of Vasomax. Firm states still $60M cash. Shares out, average >11 Mio. I think I will put it on the watchlist as co doesn't burn that much money and seems to be able to generate some revenues. It may rise to $20 again after this and soon-to-be made annoucements to promote Vasomax. Though, numbers are unaudited. And, stemming from the last annual reports (31.3.1998), Zonagen is notorious in activating money from exercising options granted to directeurs and staff, recognizing portions of it pro rata. Who knows whether all of the options will ever be exercised esp. those with a $30 Strike. Still, the market risk resulting from this recognition of income is not stated in the 10A. Well, numbers are peanuts. sec.yahoo.com Christian

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next